ClinicalTrials.gg
Not yet recruitingNCT07891377Updated Oct 23, 2026

HEC53856 Tablets for Chemotherapy-induced Anemia in Non-myeloid Malignancies

A Phase 2 interventional study of HEC53856 tablet and rHuEPO injection in Chemotherapy-induced Anemia and Non-Myeloid Malignancy, sponsored by Sunshine Lake Pharma Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Sunshine Lake Pharma Co., Ltd. · Phase 2, Interventional, and Treatment

Updated Oct 23, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 115 studies in Anemia with a site in China — 33 open to participants now, 42 under way, 8 of them phase 3. Anemia · China.

Planned enrollment
36th of 97
160 · median 120
Started
2026
with 4 others
Phase 2
22 of 115
6 open now
Primary completion
2028-02
later than 37 of 41 live
Registered
115th of 115
by date

Among the 115 studies in Anemia with a site in China, this one is the 36th largest by planned enrollment of the 97 interventional ones that give a count, is one of 5 that started in 2026, is one of 22 in phase 2, reaches primary completion later than 37 of the 41 other live ones, and was the 115th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

33 of the 115 studies in Anemia with a site in China are open now. Recruiting first, the newest first:

28 more — sign in →

All 33 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Anemia with a site in China, or all of them as a file.
02

Study summary

A Phase II clinical trial to evaluate the efficacy and safety of different dosing regimens of HEC53856 tablets compared to rHuEPO injection in participants of the CIA trial.

Read the detailed description

This study is a multicenter, randomized, open-label, phase II clinical trial with a positive control, aimed at evaluating the efficacy and safety of different dosing regimens of HEC53856 tablets compared to Recombinant Human Erythropoietin (rHuEPO) injection in participants of the Chemotherapy-induced Anemia (CIA) trial.

03

Conditions studied

  • Chemotherapy-induced Anemia
  • Non-Myeloid Malignancy

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old, weight ≥ 40 kg, gender not limited;
  • Diagnosed as non myeloid malignant tumor through histology or cytology;
  • Bone marrow suppression chemotherapy related anemia, defined as ≤ 100 g/L during the screening period, and according to the researcher's judgment, there are records showing that the Hb level of the trial participants has decreased by ≥ 10 g/L after the start of previous chemotherapy;
  • Plan to receive at least 6 weeks of tumor treatment simultaneously ;
  • Eastern Cancer Collaboration Group () Physical Fitness Status Score: 0-2 points;
  • Expected survival time ≥ 6 months;
  • ferritin ≥ 50 ng/mL and transferrin saturation (TSAT) ≥ 10%;
  • Participants in the experiment must have appropriate organ function and meet all of the following laboratory test results before enrollment:

    1. Liver function: and AST ≤ 3 × ; Serum ≤ 1.5 × ULN;
    2. Renal function: According to the 4-variable equation, the estimated glomerular filtration rate (eGFR) is ≥ 50 mL/min/1.73 m2.
  • Non lactating female trial participants; For female trial participants with fertility: During the screening period, the blood pregnancy test must benegative, and from signature through 3 months following the last study treatment dose have no plan for oocyte retrieval for in-vitro fertilization (IVF) and must agree to take effective measures.

For male trial participants who have not been sterilized: from informed consent signature through 3 months following the last study treatment dose,have no plan to donate sperm and must agree to take effective contraceptive measures.

The definition and contraception guidelines for "women with fertility" can be found in section 15.3.

  • Voluntarily participate in this study and sign a written informed consent form.

Exclusion criteria

Exclusion Criteria:

  • Participants receiving bone marrow suppressive chemotherapy with an expected outcome of cure;
  • Uncontrolled central nervous system ; Or confirm central nervous system metastasis, but have not been stabilized for more than 4 weeks after anti-tumor treatment (definition of stable central nervous system metastasis: no new neurological deficits caused by central nervous system metastasis have been found, no new lesions have been detected by central nervous system imaging examination, and no /steroid treatment is needed); Or malignant neoplasms with primary central nervous system origin or bone-marrow involvement, or malignant tumors of the myeloid system (such as chronic myeloid leukemia, etc.);
  • Hematocrit (HCT) ≥ 36%;
  • Plan to undergo major surgery during the treatment period;
  • traditional Chinese patent medicines and simple preparations that has received anemia treatment within 2 weeks before randomization or RBC infusion or anemia treatment drugs within 4 weeks before randomization, including but not limited to erythropoiesis stimulators (ESAs) and their derivatives, hypoxia inducible factor proline hydroxylase (HIF-PHD) inhibitor, androgen and anabolic hormone drugs;
  • Receive (including attenuated live vaccines) within the first 4 weeks of randomization;
  • Participants who have participated in any interventional clinical trials and received drugs or medical device interventions within the first 4 weeks of randomization (excluding participants in overall survival follow-up trials who only participated in one study), or plan to use these drugs during their participation in this clinical trial;
  • Only accept hormone preparations, biologics, novel agents (such as and PD-L1 immune checkpoint inhibitors), targeted biotherapy, or radiation therapy to treat/control their tumors. Note: If chemotherapy is combined with these drugs or if the treatment received contains antibody conjugated drugs (ADCs), it can be included in the study;
  • Currently using or expected to use dapsone during the study treatment period;
  • There is known, active, or chronic bleeding present;
  • Anemia of clinical significance caused by other etiologies, such as iron deficiency, vitamin B12 or folate deficiency, anemia, hemolysis, hemorrhage, sickle cell anemia or thalassemia, etc;
  • Persistent inflammation/autoimmune diseases that are or uncontrolled (such as rheumatoid arthritis, Crohn's disease, celiac disease, etc.);
  • Any of the following cardiovascular risk factors:

    1. Any history of significant clinical arrhythmia (such as rapid atrial fibrillation, high-grade atrioventricular block, ventricular tachycardia, ventricular fibrillation, or apical torsion ventricular tachycardia);
    2. (LVEF) is less than 50% during the screening period;
    3. Individuals who have had any of the following diseases within the first 12 months of randomization: myocardial infarction, coronary artery bypass grafting or peripheral artery bypass grafting surgery, heart failure ( functional class III-IV), etc; Or have unstable angina pectoris within the first 6 months of randomization; Or a history of severe valvular or endocardial disease that may put trial participants at risk of thromboembolism;
    4. Uncontrollable hypertension (despite receiving antihypertensive medication, systolic blood pressure>160 mmHg, or diastolic blood pressure>100 mmHg), or a history of hypertensive crisis or hypertensive encephalopathy;
  • Within the first 6 months of randomization, there has been a history of thrombosis or embolism events, such as cerebrovascular accidents (including , excluding lacunar cerebral infarction), deep vein thrombosis, pulmonary embolism, etc., or receiving therapeutic doses of anticoagulant drugs within 2 weeks before the first medication;
  • Prior to randomization, the investigater determined the presence of uncontrollable active systemic infections;
  • Suffering from congenital or acquired immune dysfunction (such as infected individuals); Or partcipants with active virus (HBV) or virus (HCV) infection: who are HBsAg positive or HBcAb positive during the screening period need to be tested for HBV DNA, and HBV DNA quantification ≥ 104 cps/mL or ≥ 2000 IU/mL; Participants with positive HCV antibody test results require further HCV RNA testing, and have positive quantitative HCV RNA;
  • History of severe liver disease or active liver disease;
  • Clinically significant gastrointestinal abnormalities that may affect drug intake, transport, or absorption (such as inability to swallow, chronic diarrhea, intestinal obstruction, etc.), or total gastrectomy;
  • Individuals with a history of severe allergic diseases or drug allergies, or known allergies to rHuEPO injection or HEC53856 tablets;
  • Individuals with a history of abuse of psychotropic drugs and unable to quit, or those with mental disorders;
  • Researchers believe that patients with other serious acute or chronic diseases are not suitable to participate in clinical trials.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    HEC53856 Tablets

    Participants in the experimental cohort will take HEC53856 tablets orally, each treatment cycle is 3 weeks. The treatment will continue until the termination criteria are met, and the dosage can be adjusted according to the protocol standards.

    Drug: HEC53856 tablet

  • Active comparator
    rHuEPO injection

    Participants in the positive control group are administered rHuEPO injection. Each treatment cycle is 3 weeks and treatment will continues until the termination criteria are met. The dosage can be adjusted according to the instructions or plan.

    Drug: rHuEPO injection

Interventions

  • The experimental cohort is divided into four groups: 20 mg once a day (QD) group, 40 mg QD group, 60 mg QD group, and 100 mg three times a week \[TIW\] group. Participants in the experimental cohort will take HEC53856 tablets orally either in the fasted state or after meals.

  • DrugrHuEPO injection

    rHuEPO Injection 36000 IU will be subcutaneously administered once weekly \[QW\].

06

What researchers measure

Primary outcomes

  1. The compliance rate of hemoglobin (Hb) in trial participants at week 7

    The proportion of participants who met the hemoglobin (Hb) standard (defined as 100\<Hb ≤ 120 g/L) in the 7th week

    Time frame: Week 7

Secondary outcomes

  1. Hemoglobin (Hb) Response Rate

    The proportion of participants achieving Hb targets at each preset visit point during the trial period (including the study treatment end visit; excluding the 7th week)

    Time frame: Up to around 15 weeks

  2. The average Hb compliance rate of participants at each preset visit point during the trial period

    During the trial, the average Hb target achievement rate at the preset study visits was calculated.

    Time frame: Up to around 15 weeks

  3. Mean change of Hb

    Mean change from baseline in hemoglobin level assessed from Week 7 through the end-of-treatment visit.

    Time frame: From Week 7 to around week 15

  4. The proportion of trial participants with Hb increased by ≥10 / 15 / 20 g/L from baseline

    Proportion of participants achieving hemoglobin increase of at least 10 g/L, 15 g/L, or 20 g/L relative to baseline.

    Time frame: Up to around 15 weeks

  5. The time when Hb increased by ≥10 /15/20 g/L compared to baseline

    Time from randomization to first occurrence of hemoglobin increase of at least 10 g/L, 15 g/L, or 20 g/L relative to baseline.

    Time frame: Up to around 15 weeks

  6. The proportion of trial participants whose chemotherapy dosage is reduced or suspended due to anemia.

    Study the proportion of trial participants whose chemotherapy dosage is reduced or suspended due to anemia during treatment.

    Time frame: Up to around 15 weeks

  7. Proportion of participants with non-response

    Proportion of participants meeting non-response criteria defined as requirement for red blood cell transfusion or hemoglobin less than 60 g/L, assessed from Week 5 to end of treatment.

    Time frame: From Week 5 to around week 15

  8. Number and volume of red blood cell transfusions

    Number of red blood cell transfusions and transfusion volume from baseline to the end of treatment.

    Time frame: From baseline to around week 15

  9. Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)

    Adverse events in this study will be evaluated according to CTCAE V6.0

    Time frame: Up to around 15 weeks

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Feb 2028, 14 months later.

Of 58 industry-sponsored phase 2 interventional studies under Anemia, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 40. This study's planned 14 months is below that.

Counting every sponsor, half of 88 studies reached it within 28 months; a quarter within 16 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 14, 2026
First posted
Oct 23, 2026
StartEst.
Dec 2026
Primary completionEst.
Feb 2028
CompletionEst.
May 2029
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07891377
Responsible party
Sponsor
First posted
Oct 23, 2026
Start date
Dec 2026 (estimated)
Primary completion
Feb 2028 (estimated)
Completion
May 2029 (estimated)
Last update
Oct 23, 2026

Study contacts

Lu Shun, MD
Contact
shun_lu@hotmail.com
86+021-22200000-3403

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: HEC53856

Start the discussion